...
首页> 外文期刊>Infection and immunity >Attenuated Shigella flexneri 2a Vaccine Strain CVD 1204 Expressing Colonization Factor Antigen I and Mutant Heat-Labile Enterotoxin of Enterotoxigenic Escherichia coli
【24h】

Attenuated Shigella flexneri 2a Vaccine Strain CVD 1204 Expressing Colonization Factor Antigen I and Mutant Heat-Labile Enterotoxin of Enterotoxigenic Escherichia coli

机译:减毒志贺氏菌2a疫苗株CVD 1204表达定殖因子抗原I和产肠毒素大肠杆菌的突变热不稳定肠毒素

获取原文
           

摘要

A multivalent live oral vaccine against both Shigellaspp. and enterotoxigenic Escherichia coli (ETEC) is being developed based on the hypothesis that protection can be achieved if attenuated shigellae express ETEC fimbrial colonization factors and genetically detoxified heat-labile toxin from a human ETEC isolate (LTh). Two detoxified derivatives of LTh, LThK63 and LThR72, were engineered by substitution—serine to lysine at residue 63, or lysine to arginine at residue 72. The genes encoding these two derivatives were cloned separately on expression plasmids downstream from the CFA/I operon. Following electroporation into S. flexneri 2a vaccine strain CVD 1204, coexpression of CFA/I and LThK63 or LThR72 was demonstrated by Western blot analysis, GM1 binding assays, and agglutination with anti-CFA/I antiserum. Hemagglutination and electron microscopy confirmed surface expression of CFA/I. Guinea pigs immunized intranasally on days 0 and 15 with CVD 1204 expressing CFA/I and LThK63 or LThR72 exhibited high titers of both serum immunoglobulin G (IgG) and mucosal secretory IgA anti-CFA/I; 40% of the animals produced antibodies directed against LTh. All immunized guinea pigs also produced mucosal IgA (in tears) and serum IgG anti-S. flexneri 2a O antibodies. Furthermore, all immunized animals were protected from challenge with wild-type S. flexneri 2a. This prototype Shigella-ETEC hybrid vaccine demonstrates the feasibility of expressing multiple ETEC antigens on a single plasmid in an attenuated Shigella vaccine strain and engendering immune responses against both the heterologous antigens and vector strain.
机译:一种针对两种志贺氏菌 spp的多价活口服疫苗。并基于以下假说开发肠毒素性大肠埃希氏菌(ETEC):假若减毒志贺氏菌表达ETEC纤维定居因子和从人类ETEC分离物(LTh)遗传解毒的不耐热热毒素,就可以实现保护。通过置换工程化了LTh的两种解毒衍生物LThK63和LThR72-残基63处的丝氨酸为赖氨酸,或残基72处的赖氨酸为精氨酸。编码这两种衍生物的基因分别克隆在CFA / I操纵子下游的表达质粒上。在电穿孔成 S后。免疫印迹分析,GM 1 结合试验以及抗CFA / I抗血清的凝集证实了flexneri 2a疫苗株CVD 1204,CFA / I和LThK63或LThR72的共表达。血凝和电子显微镜检查证实了CFA / I的表面表达。在第0天和第15天用表达CFA / I和LThK63或LThR72的CVD 1204鼻腔免疫的豚鼠表现出高滴度的血清免疫球蛋白G(IgG)和粘膜分泌性IgA抗CFA / I。 40%的动物产生针对LTh的抗体。所有免疫的豚鼠也产生粘膜IgA(流泪)和血清IgG抗-S。 flexneri 2a O抗体。此外,保护所有免疫的动物免受野生型 S的攻击。 flexneri 2a。该原型志贺氏菌 -ETEC混合疫苗证明了在减毒的志贺氏菌疫苗株的单个质粒上表达多种ETEC抗原并引起针对异源抗原和载体的免疫应答的可行性应变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号